Effect of the chronic medication use on outcome measures of hospitalized Covid-19 patients

Evidence from big data

Datos Bibliográficos

ID22073648
AutoresMohammad‐Reza Malekpour (0000-0002-8648-5402, Tehran University of Medical Sciences), Mohammad-Reza Malekpour, Mohsen Abbasi‐Kangevari (0000-0001-8405-7482, Tehran University of Medical Sciences), Mohsen Abbasi-Kangevari, Ali Shojaee (0009-0009-0438-9045, Tehran University of Medical Sciences), Sahar Saeedi Moghaddam (0000-0002-3112-9179, Kiel Institute for the World Economy), Seyyed-Hadi Ghamari, Seyyed‐Hadi Ghamari (0000-0001-6028-3303, Tehran University of Medical Sciences), Mohammad‐Mahdi Rashidi (0000-0002-7460-6000, Tehran University of Medical Sciences), Mohammad-Mahdi Rashidi, Alireza Namazi Shabestari (0000-0003-0817-0883, Tehran University of Medical Sciences), Mohammad Effatpanah (0000-0001-5344-7699, Imam Khomeini Hospital), Mohammadmehdi Nasehi (Shahid Beheshti University of Medical Sciences), Mehdi Rezaei (0000-0002-0468-5065, Tehran University of Medical Sciences), Farshad Farzadfar (0000-0001-8288-4046, Tehran University of Medical Sciences, autor de correspondencia)
Año2023
Volumen11
Páginas1061307-1061307
Fecha de publicación2023-02-24
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaFrontiers in Public Health (JOURNAL)
Identificadores de la revistaISSN: 2296-2565 • E-ISSN: 2296-2565
EditorialFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2023.1061307
PMID36908454
OpenAlexW4321789572
IdiomaEN
Citas recibidas1
Referencias citadas39

Background: Concerns about the role of chronically used medications in the clinical outcomes of the coronavirus disease 2019 (COVID-19) have remarkable potential for the breakdown of non-communicable diseases (NCDs) management by imposing ambivalence toward medication continuation. This study aimed to investigate the association of single or combinations of chronically used medications in NCDs with clinical outcomes of COVID-19. Methods: This retrospective study was conducted on the intersection of two databases, the Iranian COVID-19 registry and Iran Health Insurance Organization. The primary outcome was death due to COVID-19 hospitalization, and secondary outcomes included length of hospital stay, Intensive Care Unit (ICU) admission, and ventilation therapy. The Anatomical Therapeutic Chemical (ATC) classification system was used for medication grouping. The frequent pattern growth algorithm was utilized to investigate the effect of medication combinations on COVID-19 outcomes. Findings: Aspirin with chronic use in 10.8% of hospitalized COVID-19 patients was the most frequently used medication, followed by Atorvastatin (9.2%) and Losartan (8.0%). Adrenergics in combination with corticosteroids inhalants (ACIs) with an odds ratio (OR) of 0.79 (95% confidence interval: 0.68-0.92) were the most associated medications with less chance of ventilation therapy. Oxicams had the least OR of 0.80 (0.73-0.87) for COVID-19 death, followed by ACIs [0.85 (0.77-0.95)] and Biguanides [0.86 (0.82-0.91)]. Conclusion: The chronic use of most frequently used medications for NCDs management was not associated with poor COVID-19 outcomes. Thus, when indicated, physicians need to discourage patients with NCDs from discontinuing their medications for fear of possible adverse effects on COVID-19 prognosis

Aspirin · Confidence interval · Intensive care medicine · Intensive care unit · Odds ratio · Retrospective cohort study · COVID-19 Clinical Research Studies · Long-Term Effects of COVID-19 · Medicine · Pharmacological Receptor Mechanisms and Effects · Emergency Medicine · Internal Medicine